BostonSight

BostonSight BostonSight is a nonprofit that advances the treatment of diseased or damaged corneas and dry eye. Prasad Eye Institute in the Middle East and India.

BostonSight restores sight and improves the quality of life for individuals with ocular surface disease. We developed Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE)™, a medical treatment to improve visual function for those suffering from complex corneal disease. During treatment, PROSE Clinical Fellows custom design FDA-cleared prosthetic devices to replace or support damaged ocul

ar functions, improving vision and reducing pain and light sensitivity. For many patients, BostonSight PROSE™ treatment is their only option to restore their vision and end the suffering from critical and devastating eye issues. BostonSight PROSE treatment is available at top medical centers around the U.S., Canada, and India. Find a PROSE provider at http://www.bostonsight.org/find-a-provider/. BostonSight SCLERAL was launched to expand access to global scleral lens technology. Eye care practitioners can achieve an effective scleral lens fit that provides optimal vision and comfort for patients while attaining long-term eye health. BostonSight SCLERAL has partnerships around the world: ABB Optical in North America, Spectrum International in Latin America, and L.V.

As ALS awareness month wraps up, we'd like to share Jacob's story. Jacob was diagnosed with ALS in 2022, since then he h...
05/26/2026

As ALS awareness month wraps up, we'd like to share Jacob's story. Jacob was diagnosed with ALS in 2022, since then he has started wearing scleral lenses to help retain his ability to communicate. Read more about Jacob's journey:

How Scleral Lenses Helped an ALS Patient Maintain Communication

Meet Jacob

When 23-year-old Jacob Harper from Winfield, West Virginia, first heard the words “You have ALS,” in March 2022, he and his father sat in shock. Neither had a clear understanding of what the diagnosis meant. His mother, however, turned pale—she knew the weight of those three letters. Amyotrophic lateral sclerosis, or ALS, is a relentless disease. For Jacob, it was not just ALS but an ultra-rare genetic version, linked to the P525L FUS mutation. Doctors told him to expect only one to three years.

Jacob, once an avid outdoorsman who loved hunting, fishing, and working as a machinist and a welder, suddenly faced a future of increasing paralysis and loss. Yet, through determination, faith, and access to an experimental drug called ION363—nicknamed “Jacifusen”—he has lived beyond those initial predictions. Even as the disease advanced, Jacob and his family found new ways to fight for quality of life.

One of the most unexpected breakthroughs came not from a drug or machine, but from a pair of lenses.

Losing the ability to communicate

As ALS progressed, Jacob eventually lost the ability to move his eyes. He could no longer blink, and his eyelids wouldn’t stay open. Severe dry eye followed, leaving his eyes painfully irritated and threatening to take away his ability to watch television, enjoy car rides, or even communicate. At times, his parents resorted to using cosmetic tape to hold his eyelids open. It was an exhausting, imperfect solution that underscored how fragile his remaining independence had become.

How scleral lenses help ALS patients retain communication longer

Enter scleral lenses. Traditionally used for patients with corneal disease or extreme dry eye, these specialized contact lenses are larger than normal and vault over the eye, creating a reservoir of fluid that bathes the cornea. Jacob’s care team at The Ohio State University had never tried them in someone with ALS before, but they were willing to innovate. Working with Dr. Stephanie Pisano and her team, including a dedicated resident, Dr. Shihij Takoo, Jacob went through multiple fittings to find lenses that worked. They had to account for astigmatism, depth, and comfort, making careful adjustments along the way.

The impact was immediate. With the scleral lenses in place, Jacob’s eyes could stay open and moist, protected from damage and discomfort. Combined with cosmetic tape, the lenses allowed him to keep his eyes open long enough to enjoy daily life again and, most importantly, stay engaged with the people he loves. His father calls the lenses “a blessing,” explaining, “I don’t know what we would do if it had not been for the scleral lenses. In a world where we had already lost almost everything, and we only had communication left, these lenses made sure we were able to hang on to this piece of dignity.”

Maintaining dignity

Communication is one of the cruelest battlegrounds in ALS. Before his eye paralysis, Jacob was lightning-fast on an eye-gaze computer system, astonishing his speech therapist with his speed. He could email, text, and even shop online almost as quickly as before his diagnosis. In fact, it was almost as if his family could have regular conversations with Jacob. As his voice deteriorated, Jacob’s family connected with Bridging Voice, a nonprofit based in New York City, who assists ALS families with communication technology. They were put in touch with ElevenLabs, who uses clips of a person’s voice to create an electronic voice. Using videos, they created an AI duplicate that sounded almost identical to Jacob.

When he lost the ability to move his eyes, that option disappeared. Today, he communicates using a neuro-node system connected to his leg muscles. Though slower, it still allows him to share his thoughts and direct his smart home devices. Today, scleral lenses make it possible for him to keep his eyes open, protected, and moisturized, allowing him to interact with his environment and preserve the vital connection between his mind and the outside world.

For the Harper family, the lenses are more than a medical tool. They are a bridge. They have enabled Jacob to remain present in everyday moments, whether watching movies with his parents, listening to vinyl records, or taking long drives, where his father straps him into his beloved Mustang and takes him out on the open road.

ALS is a disease defined by relentless loss: the loss of movement, speech, independence, and time. But in Jacob’s case, scleral lenses hit the pause button, allowing him to maintain communication longer. They offer comfort, vision, and dignity in the face of one of life’s harshest challenges. And in doing so, they keep open a window to the world that would have otherwise closed too soon.

Learn more about Jacob’s journey at

The Dry Eye Foundation is hosting a Dry Eye Advocacy Day in Washington DC from July 16-17, 2026. All ocular surface dise...
05/13/2026

The Dry Eye Foundation is hosting a Dry Eye Advocacy Day in Washington DC from July 16-17, 2026. All ocular surface disease patients are welcome and travel scholarship to come to DC will be available! You can join an info session on 4/23, 5/28, or 6/18 to learn more about how to prepare and what to expect. Our info sessions will include a presentation on logistics, time to speak with a participant in last year’s Advocacy Day, and plenty of time for Q&A. You can learn more and register at dryeyefoundation.org/dc-2026.

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular sur...
04/03/2026

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular surface ecosystem) is a treatment pioneered by BostonSight. For thousands of patients suffering from the most complex ocular surface diseases, including keratoconus, dry eye disease, ocular GVHD, and corneal transplant complications, PROSE is often the ideal, and sometimes only, treatment capable of restoring visual function and reducing eye pain and light sensitivity, and all without surgery.

Join us on April 22nd, for a 1-hour informational webinar where BostonSight's Chief Medical Officer, Dr. Dan Brocks, and Clinic Director, Darlene Riordan, provide information about PROSE treatment and how to access it. You'll also hear from Bob, our PROSE patient representative.

Join us Wednesday, April 22nd, 2026
8:00 - 9:00 pm EDT

Register today: https://us02web.zoom.us/webinar/register/WN_yDxUJecLQneW8eWqaoOHFQ?ampDeviceId=085eec18-febb-4287-8cde-568178345b7f&SessionId=1775245669921&DeviceId=085eec18-febb-4287-8cde-568178345b7f&SessionId=1775245669921&_gl=1*zqvqv4*_gcl_au*NDAzODUzMDAwLjE3NzA3NDQyNzA.*_ga*MTQ5ODkzNjcwOS4xNzczMjQzODcw*_ga_L8TBF28DDX*czE3NzUyNDU2NzEkbzgkZzEkdDE3NzUyNDU2NzQkajU3JGwwJGgw #/registration

February 28th is Rare Disease Day. At BostonSight we see many patients with rare diseases. We just want to say; we see y...
02/28/2026

February 28th is Rare Disease Day.

At BostonSight we see many patients with rare diseases. We just want to say; we see you, we hear you, and we strive to support our patients in any way we can.❤️

Hear directly from our patients: https://www.bostonsight.org/patient-stories/

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular sur...
02/25/2026

Have you ever wondered about PROSE® treatment and how it might help you? PROSE (prosthetic replacement of the ocular surface ecosystem) is a treatment pioneered by BostonSight. For thousands of patients suffering from the most complex ocular surface diseases, including keratoconus, dry eye disease, ocular GVHD, and corneal transplant complications, PROSE is often the ideal, and sometimes only, treatment capable of restoring visual function and reducing eye pain and light sensitivity, and all without surgery.

Join us on April 22nd, for a 1-hour informational webinar where BostonSight's Chief Medical Officer, Dr. Dan Brocks, and Clinic Director, Darlene Riordan, provide information about PROSE treatment and how to access it. You'll also hear from Bob, our PROSE patient representative.

Join us Wednesday, April 22nd, 2026
8:00 - 9:00 pm EDT

Register today: https://us02web.zoom.us/webinar/register/WN_yDxUJecLQneW8eWqaoOHFQ #/registration

Due to inclement weather, BostonSight will have a delayed opening until 10:00am EST on Tuesday, February 24th, 2026.Cust...
02/24/2026

Due to inclement weather, BostonSight will have a delayed opening until 10:00am EST on Tuesday, February 24th, 2026.

Customers contacting fitting consultancy may experience delays.

Due to inclement weather, BostonSight will be closed on Monday, February 23rd, 2026.Customers contacting fitting consult...
02/22/2026

Due to inclement weather, BostonSight will be closed on Monday, February 23rd, 2026.

Customers contacting fitting consultancy may experience delays.

BostonSight Unveils 5-Year Roadmap to Advance Scleral Lens Technology, Research, and EducationNeedham, Mass. – February ...
02/17/2026

BostonSight Unveils 5-Year Roadmap to Advance Scleral Lens Technology, Research, and Education

Needham, Mass. – February 17, 2026. BostonSight® today announced a transformative 5-year strategic roadmap aimed at redefining ocular surface treatment through groundbreaking advancements in clinical research, education, and specialty lens technology. The organization has designated key leadership roles to lead initiatives that accelerate innovation and collaboration, with the goal of positively impacting patient lives around the world.

Dr. Karen Carrasquillo, OD, PhD, FAAO, FSLS, FBCLA, BostonSight’s Chief Innovation and Education Officer and Andrew Heim, Chief Technology Officer, will spearhead BostonSight’s innovation and technology strategy. They will be joined in these initiatives by Chirag Patel, OD, FAAO, Director of Innovative Technologies, and Olga Tomashevskaya, Director of Engineering. BostonSight will seek to partner with scientific, engineering, and clinical communities worldwide to revolutionize the way specialty lens treatment is delivered through innovative platforms, tools, and education.

Mr. Heim joined BostonSight in 2025 as the organization’s first CTO, bringing more than 15 years of experience in software and technical development, including nearly a decade of leading high-performing technical teams.

“Andrew brings deep expertise in technology as well as a strong understanding of BostonSight’s mission and goals,” said Sara Yost, MBA, BostonSight President and CEO. “He will be dedicated to ensuring that BostonSight stays at the forefront of technological innovation, so we not only meet, but exceed, customer expectations.”

Mr. Heim’s focus includes aligning technology with business objectives, enhancing clinical decision-making through artificial intelligence, and ensuring a secure, scalable infrastructure that supports BostonSight’s growing global operations. He will be instrumental in upholding customer and partner trust through rigorous data protection practices and training. In addition, Mr. Heim and Dr. Carrasquillo will partner on leveraging technology to expand the global accessibility of BostonSight’s educational platforms.

In addition to being a PROSE® Provider, Dr. Patel explores the intersection of patient care with technology. His research of corneo-scleral data has advanced BostonSight’s data-driven scleral lens designs to improve fitting efficiency and effectiveness. In partnership with Ms. Tomashevskaya, Dr. Patel is also developing novel approaches to enhance lens optical properties.

“Our mission is driven by a simple yet powerful belief: everyone who needs a specialty lens—no matter where they are in the world—should have access to the best care and technology available,” said Ms. Yost. “By investing in these initiatives and empowering innovative leaders, we are shaping the future of specialty lens technology while supporting practitioners with the knowledge and skills to deliver meaningful change for their patients.”

https://www.bostonsight.org/bostonsight-unveils-5-year-roadmap-to-advance-scleral-lens-technology-research-and-education/

Please note BostonSight, including lab and consultation, will be closed on Monday, February 16th, 2026.
02/12/2026

Please note BostonSight, including lab and consultation, will be closed on Monday, February 16th, 2026.

Michelle Thezin Kong, OD, Joins BostonSight as PROSE ProviderNeedham, Mass. –February 3, 2026.  BostonSight® announced t...
02/03/2026

Michelle Thezin Kong, OD, Joins BostonSight as PROSE Provider

Needham, Mass. –February 3, 2026. BostonSight® announced today that Michelle Thezin Kong, OD, has joined BostonSight as its newest PROSE® Provider. Dr. Kong joins existing PROSE Providers, Drs. Bita Asghari, Karen Carrasquillo, Alan Kwok, and Chirag Patel.

Dr. Kong received her Doctor of Optometry from the University of California (UC) Berkeley and completed her residency with programs at the New England College of Optometry, the Massachusetts Eye and Ear Infirmary, BostonSight, and Andover Optometry on Central. Dr. Kong also completed clinical internships at the California School for the Blind, UC Berkeley Meredith Morgan Eye Center, the VA Palo Alto Health Care System, and West Oakland Health Center. Most recently, she practiced at Atrius Health, where she fit patients with specialty lenses.

“Welcoming Dr. Kong to our clinical team is incredibly exciting for BostonSight and for the patients we serve,” said Sara Yost, President and CEO of BostonSight. “By expanding our team, we’re able to meet the increasing demand for our specialized care, and Dr. Kong’s impressive training reflects the deep commitment to excellence in patient care that defines BostonSight.”

Dr. Kong is a GPLI Resident Advisory Board Member and is fluent in English and Burmese.

https://www.bostonsight.org/michelle-thezin-kong-od-joins-bostonsight-as-prose-provider/

Address

464 Hillside Avenue, Ste 205
Needham Heights, MA
02494

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 4pm

Telephone

+17817267337

Website

https://www.bostonsightscleral.org/

Alerts

Be the first to know and let us send you an email when BostonSight posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Category